Dr Patrick Salmon former Senior Medical Assessor at the Irish Medicines Board has joined NDA Advisory Board.
Dr Salmon is an expert in clinical development, strategies and a specialist in pharmaceutical medicine, with almost 25 years regulatory experience at both national and EU level.
His in depth regulatory expertise in rare diseases and other special therapeutic areas such as ophthalmology and the interrelated working of EMA’s committees and the CMDh will be a superb asset to the Advisory Board.
Dr Werner Van den Eynde, Vice President NDA Advisory Board, commented on the appointment:
“I’m very happy to welcome Dr Patrick Salmon on board as our newest Advisory Board Member. His expertise in regulatory affairs, clinical development and orphan medicinal products will be of tremendous value to our clients, enabling us to help them succeed in bringing their new medicinal products to the market”.
His previous roles include: Former Senior Medical Assessor at the Irish Medicines Board, (the Health Products Regulatory Authority), Committee for Human Medicinal Products Member (previously CPMP), Ireland, Committee for Orphan Medicinal Products Member Ireland, chair of CHMP ad hoc SmPC working party, chair of CMD(h) subgroup on SmPC Harmonisation and chair of working Group on Radiopharmaceuticals.
Dr Salmon has joined and is now part of the NDA Advisory Board, a unique team of experts comprising some of the most well-known names in the industry, many of whom have been involved in designing the regulatory and HTA systems in place today. Together, they provide strategic advice and unbiased second opinions to pharmaceutical clients during part of, or the complete end-to-end drug development life cycle. This also includes support and advice during interaction with regulatory agencies, be it at scientific advice, during review of a marketing authorisation application or at any stage post-authorisation
NDA media contact: firstname.lastname@example.org
NDA is an independent consulting group with offices in Stockholm, London, Zürich, Munich, Princeton, Boston and San Francisco. Its mission is to ensure that good medicines reach patients without unnecessary delay. It accomplishes this by providing the pharmaceutical industry with a comprehensive range of professional drug development services focusing on regulatory affairs, health technology assessment, pharmacovigilance and quality assurance. NDA’s team of more than 150 full time professionals is comprised of more than 25% ex-regulators from major EU Agencies, and a specialist Advisory Board consisting of Europe’s leading regulatory and HTA experts. The NDA Advisory Board provides scientific advice to pharmaceutical companies supporting them in gaining fast and constructive assessment of applications from regulatory agencies and HTA bodies. www.ndareg.com